Healthcare Industry News: drug-eluting stent
News Release - June 2, 2008
Long-Term Financial Benefits of Drug-Eluting Stents Becoming EvidentNew York, June 2, 2008 --(HSMN NewsFeed)--Each year in the United States alone, almost 1 million people with coronary artery disease are treated with a percutaneous coronary procedure (PCI); worldwide the number is about 2.1 million. Up to 50% will experience restenosis – the re-narrowing of the coronary artery – within three to six months. To prevent this, stents are delivered into the artery during about 70% of PCI procedures.
According to a new report by Kalorama Information, Major World Markets for Stents and the Economics of Drug-Eluting Technology, the current market for coronary stents in the seven major world healthcare markets is $4.9 billion.
Recently, stents have been developed that are covered with drugs being released over time in order to reduce the risk of restenosis caused by cellular proliferation. The market effects of these new drug-eluting stents (DES) began in 2003. Today they represent 69.2% of the total coronary stent market, which is expected to grow at a rate of about 4.6% now that the shock that surrounded the alleged DES problems has dissipated.
“Though drug-eluting stents cost 3 to 4 times as much as bare metal stents, when one examines their cost-effectiveness, the case is clear,” notes Kalorama analyst Kenneth Krul. “They remain an exciting innovation that will be a major part of cardiovascular intervention technologies over the next ten years, and it should become increasingly evident that DES use does in fact result in reduced long-term healthcare costs and improved economic outcomes."
Kalorama Information’s report Major World Markets for Stents Major World Markets for Stents and the Economics of Drug-Eluting Technology focuses on the market applications of current and advanced technologies in the development of coronary stents, with an emphasis on drug-eluting stents. The market analysis covers the seven major world healthcare markets (US, France, Germany, Italy, Japan, Spain and the United Kingdom). Current and future trends, market size, projections, and company profiles are also provided. The report can be purchased by visiting http://salesandmarketingnetwork.com/reports.php?ID=2610
About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. Kalorama routinely assists media with healthcare topics, and can provide experts to speak about markets in the life sciences industry.
Source: Kalorama Information
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.